Table 1.
Clinicopathologic characteristics of the 7458 enrolled patients
| Factors | N | % |
|---|---|---|
| Age at diagnosis (years old) | ||
| < 35 | 557 | 7.5 |
| 35–50 | 4464 | 59.9 |
| > 50 | 2437 | 32.6 |
| Operation methods | ||
| BCS | 3451 | 46.3 |
| Mastectomy | 4005 | 53.7 |
| Unknown | 2 | 0 |
| T stage | ||
| T0 | 1 | 0 |
| T1 | 4013 | 53.8 |
| T2 | 3019 | 40.5 |
| T3 | 316 | 4.2 |
| T4 | 109 | 1.5 |
| N stage | ||
| N0 | 4270 | 57.3 |
| N1 | 2106 | 28.2 |
| N1mi | 168 | 2.3 |
| N2 | 550 | 7.4 |
| N3 | 364 | 4.8 |
| Histologic grade | ||
| G1 | 516 | 6.9 |
| G2 | 4076 | 54.7 |
| G3 | 2866 | 38.4 |
| Nuclear grade | ||
| G1 | 384 | 5.2 |
| G2 | 3572 | 47.9 |
| G3 | 2610 | 35.0 |
| GX | 3 | 0 |
| Unknown | 889 | 11.9 |
| Lymphovascular invasion | ||
| Negative | 4437 | 59.5 |
| Positive | 1686 | 22.6 |
| Unknown | 1335 | 17.9 |
| Estrogen receptor | ||
| Negative | 2921 | 39.2 |
| Positive | 4537 | 60.8 |
| Progesterone receptor | ||
| Negative | 3496 | 46.9 |
| Positive | 3962 | 53.1 |
| HER2(IHC) | ||
| Negative | 5476 | 73.4 |
| Positive | 1982 | 26.6 |
| Subtype | ||
| HR+/HER2− | 3944 | 52.9 |
| HR+/HER2+ | 970 | 13.0 |
| HR−/HER2+ | 1012 | 13.6 |
| HR−/HER2+ | 1532 | 20.5 |
| Radiation therapy | ||
| Yes | 4386 | 58.8 |
| No | 3039 | 40.7 |
| Unknown | 33 | 0.5 |
| Chemotherapy | ||
| Yes | 5316 | 71.3 |
| No | 2096 | 28.1 |
| Unknown | 46 | 0.6 |
| Antihormonal therapy | ||
| Yes | 5202 | 69.8 |
| No | 2191 | 29.4 |
| Unknown | 65 | 0.8 |
HER2 human epidermal growth factor receptor-2, IHC immunohistochemistry